Lungpacer to Showcase the Potential of Novel Technologies to Improve Lung, Heart, and Brain Health in Ventilated PatientsEXTON, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- This spring, Lungpacer Medical clinical experts and device innovators will be featured presenters at top industry events. Speakers will demonstrate how novel interventional therapies can free critically ill patients from mechanical ventilation and may help improve lung, heart, and brain health in ventilated patients.
Kevin Kearney Joins Lungpacer Medical as Chief Commercial OfficerCompany Appoints Medical Device and Healthcare Industry Veteran with 20 Years of Experience
Lungpacer Medical Announces Investigational Device Exemption (IDE) for STARI, Phase 2 Feasibility Clinical TrialThe investigational AeroNova® System delivers continual diaphragm neurostimulation in conjunction with mechanical ventilation and is designed to mitigate the negative effects of ventilation that cause multi-organ ventilator-induced injury.
Lungpacer Medical Announces Positive Results from STIMULUS Trial: Diaphragm Neurostimulation Improves Hemodynamic Performance During Mechanical VentilationThe investigational AeroNova® System delivers continual diaphragm neurostimulation in synchrony with mechanical ventilation and is designed to reduce injurious pressures from mechanical ventilation to mitigate multi-organ ventilator-induced injury to patients on ventilation
Lungpacer Medical Announces Premarket Approval for AeroPace® SystemAeroPace is a minimally invasive transvenous diaphragm strengthening neurostimulation therapy for quicker patient liberation from mechanical ventilation
Lungpacer Medical Announces PMA Submission for AeroPace® SystemAeroPace is a minimally invasive transvenous diaphragm strengthening neurostimulation therapy designed for quicker liberation from mechanical ventilation
